11:48 AM EDT, 09/16/2024 (MT Newswires) -- Kairos Pharma ( KAPA ) said Monday it priced its initial public offering of 1.55 million common shares at $4 apiece for $6.2 million in expected gross proceeds.

The offering underwriters have a 45-day overallotment option to acquire up to 232,500 additional shares.

The company expects its shares to start trading on the NYSE American Monday under the KAPA symbol.

The offering is expected to close by Tuesday, with net proceeds to go toward funding Kairos' phase 1 trial in lung cancer and phase 2 trial in prostate cancer for its lead product candidate ENV 105, among other things, the company said.